DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Vivoryon Therapeutics and Simcere Announce CDE Approval of Chinese Clinical Trial Application

Related Keywords

China ,Germany ,Munich ,Bayern ,Berlin ,Nanjing ,Jiangsu ,Amsterdam ,Noord Holland ,Netherlands ,Renhong Tang ,Jason Bao ,Halle Saale ,Sophia Hergenhan ,Manuela Bader ,Jian Hou ,Michael Schaeffer ,Simcere Pharmaceutical Group ,Drug Administration ,Trophic Communications ,Simcere Pharmaceutical Group Ltd ,Distribution Services ,National Medical Products Administration ,News Service ,China Center ,Vivoryon Therapeutics ,Simcere Announce ,Chinese Clinical Trial Application ,Euronext Amsterdam ,Drug Evaluation ,Clinical Trial Application ,Greater China ,Executive Vice President ,Chief Business Officer ,Fast Track ,Pharmaceutical Group ,Simcere Pharmaceutical Group Limited ,Board Secretary ,Corporate News ,Regulatory Announcements ,Unofficial Market ,Dgap ,News ,Vivoryon ,Herapeutics ,Simcere ,Nnounce ,Approval ,Chinese ,Linical ,Trial ,Application ,Aroglutamstat ,Im0408 ,Q912 ,Patients ,Lzheimer ,Disease ,